Genmab AS (GE91y)

TradeGate
Currency in EUR
18.00
0.00(0.00%)
Delayed Data·
Fair Value
Day's Range
17.6018.00
52 wk Range
15.8027.60
Key Statistics
Edit
Bid/Ask
18.40 / 18.50
Prev. Close
18
Open
17.6
Day's Range
17.6-18
52 wk Range
15.8-27.6
Volume
-
Average Volume (3m)
169
1-Year Change
-30.23%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GE91y Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Genmab AS Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Compare GE91y to Peers and Sector

Metrics to compare
GE91y
Peers
Sector
Relationship
P/E Ratio
0.0x−0.9x−0.5x
PEG Ratio
0.000.020.00
Price/Book
0.0x6.6x2.6x
Price / LTM Sales
0.0x7.0x2.9x
Upside (Analyst Target)
0.0%36.9%56.4%
Fair Value Upside
Unlock8.3%9.3%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

16.47
OPRA
-2.49%
93.26
CALM
-0.14%
109.60
DECK
-1.87%
121.20
QLYS
-5.63%

FAQ

What Is the Genmab AS (GE91y) Stock Price Today?

The Genmab AS stock price today is 18.00

What Stock Exchange Does Genmab AS Trade On?

Genmab AS is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Genmab AS?

The stock symbol for Genmab AS is "GE91y."

What Is the Genmab AS Market Cap?

As of today, Genmab AS market cap is 11.54B.

What is Genmab AS Earnings Per Share?

The Genmab AS EPS is 0.00.

From a Technical Analysis Perspective, Is GE91y a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.